U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07498920) titled 'Gut Microbiome in DLBCL Treated With Glofitamab' on March 23.
Brief Summary: The gut microbiome (GM) has recently emerged as one of the key modifiable factors of response and prognosis to immunotherapy in cancer patients. Currently, it is unknown if GM also modulates anti-tumor responses to T cell engagers (TCE) including glofitamab in DLBCL patients.
Study Start Date: April 01
Study Type: OBSERVATIONAL
Condition:
DLBCL
Glofitamab
Gut Biome
Intervention:
OTHER: Gut microbiome analysis
Gut microbiome analysis would be performed before and after glofitamab treatment in DLBCL patients.
Recruitment Status: NOT_YET_RECRUITING
S...